Neuromyelitis optica spectrum disorder

3 trials 3 recruiting MedDRA PT
3 Registered trials
3 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Complement inhibitor (C5) 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Phase III: 1 Phase II/III: 1 Phase II: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • F. Hoffmann-La Roche AG Commercial
    SATRALIZUMAB
    2023-507817-85-00 3 countries 2022 n=7
    Recruiting

Phase II/III

1 trial
  • Alexion Pharmaceuticals Inc. Commercial
    RAVULIZUMAB
    2023-508534-33-00 3 countries 2022 n=6
    Recruiting

Phase II

1 trial
  • Horizon Therapeutics Ireland Designated Activity Company Commercial
    IMP not specified
    2023-510007-22-00 5 countries 2022 n=5
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alexion Pharmaceuticals Inc. Commercial 1 Phase II/III 1
Horizon Therapeutics Ireland Designated Activity Company Commercial 1 Phase II 1
F. Hoffmann-La Roche AG Commercial 1 Phase III 1
New trials by year
2022
3
← All indication landscapes